Xiang-Yu Zhao

Featured in: Favicon

nature.com Favicon

onlinelibrary.wiley.com

Articles

A multifactorial risk scoring system for the prediction of early relapse in CMML patients with allo-HSCT: a nationwide representative multicenter study | Bone Marrow Transplantation

Nov 24, 2024 | nature.com | Xiao-bing Huang |Yi Luo |Yu-Hua Li |Xi Zhang |Hai Yi |Xiang-Yu Zhao | +2 more

AbstractChronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell malignancy and the only curable therapy is allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, allo-HSCT is not appropriate for all CMML patients, and relapse is the leading cause of treatment failure. This project conducted a nationwide multicenter real-world study to develop a novel prediction scoring system for early relapse.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →